MUC1 and interstitial lung disease: Kl-6 is recognized as a prognostic biomarker of Interstitial Lung Disease (ILDs), predicting response to antifibrotic therapies33,37,38, has been correlated with risk of mortality in Acute Respiratory Distress Syndrome (ARDS)39 and reported as indicator of alveolar epithelial cell damage induced by mechanical ventilatory support39.